In a setback, AstraZeneca's immunotherapy tremelimumab flunks mesothelioma test
Just weeks after AstraZeneca ($AZN) reported a success for a combination study of durvalumab and tremelimumab, the pharma giant has been forced to concede that the CTLA-4 drug tremelimumab flunked a solo challenge for mesothelioma.
Roche Partners with Blueprint Medicine on Cancer Immunotherapy
Blueprint Medicines said today it is launching a $1 billion-plus collaboration with Roche to discover, develop, and commercialize up to five small-molecule therapeutics targeting kinases deemed important in cancer immunotherapy.
The five candidates could be either single products or products to be combined with Roche therapeutics.
Roche will hold options triggered upon achievement of Phase I proof-of-concept for an exclusive license to each drug candidate developed under the collaboration.
Blueprint Medicines will primarily oversee preclinical research and clinical development for each program before Roche exercises any option for it. Should Roche exercise an option for a program, Roche will be responsible for global development for that program through Phase III clinical trials.
Jim Mellon-backed cancer drug company SalvaRx launches on Aim
Failed Polish oil and gas investor 3Legs will relaunch on the junior market as a cancer drug company backed by multi-millionaire investor Jim Mellon. In the face of collapsing commodity prices the shale business has undergone a complete transformation after it announced an £8.8m reverse takeover of cancer immunotherapy development company SalvaRx. Shares will start trading on Tuesday at 35p with a £1.95m share placing also take place.